Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
GLP1RAs Linked to Higher DR Progression Risk vs. SGLT2is
A new study published online July 19 in Diabetes, Obesity and Metabolism has highlighted significant concerns regarding the treatment of diabetic retinopathy (DR) in patients with diabetes. The research indicates that treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is…
New Insights on Retinoblastoma Treatment
Recent research presented at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting underscores significant improvements in treating retinoblastoma, a rare eye cancer affecting young children. The study reveals that advancements in treatment over the past 15 years have notably…
New Research Unveils Uveal Melanoma Metastasis Mechanisms
New research from Edith Cowan University (ECU) is shedding light on the factors driving the metastasis of uveal melanoma, the deadliest form of eye cancer known for its high rate of spreading to the liver. Uveal Melanoma Overview and Metastasis…
Samsara Vision Launches SING IMT in China
Samsara Vision announced the successful completion of the first SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) procedure in China. This milestone was achieved at the First Affiliated Hospital of Hainan Medical University Lecheng Hospital, where Professor Li Xiaorong, MD, PhD,…
Topcon and Orbis Partner to Expand DR Screening in Rwanda
Topcon Healthcare, in collaboration with Orbis International and the Rwanda International Institute of Ophthalmology (RIIO), has embarked on an initiative to enhance diabetic retinopathy screening in Rwanda. Donation of Robotic Retinal Cameras To facilitate this effort, Topcon has generously donated…
Trial Results for Susvimo Show Sustained Efficacy in DME and DR
Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…
Sydnexis Appoints Perry J. Sternberg as CEO
Sydnexis, Inc., a pioneering biopharmaceutical company dedicated to addressing pediatric myopia progression, has appointed Perry J. Sternberg as its Chief Executive Officer and as a member of its Board of Directors. Sternberg, a seasoned pharmaceutical and biotech executive with over…